In another study, even short-term dual inhibition of BRAF/MEK, when combined with anti-PD-1, was sufficient to enhance tumour immune infiltration and overall improved tumour control in a CD8 + T-cell dependent manner [28]. The gene discussed is PDCD1; the disease is neoplasm.